Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
News|Articles|August 1, 2018
- Pharmaceutical Technology\'s In the Lab eNewsletter-09-05-2018
- Volume 13
- Issue 9
Metrohm Acquires B&W Tek
Author(s)Pharmaceutical Technology Editors
The acquisition will increase Metrohm’s spectroscopy offerings and capabilities.
Advertisement
On July 27, 2018, Metrohm AG, a manufacturer of high-precision instruments for chemical analysis, announced that it acquired B&W Tek’s spectroscopy solution business, B&W Tek, as well as several subsidiaries. B&W Tek is a provider of Raman spectroscopy solutions as well as laser-induced breakdown spectroscopy technology, near-infrared spectroscopy, and ultraviolet–visible spectroscopy/ultraviolet–visible spectrometers and solutions.
According to Metrohm, the acquisition contributes to the development of the company’s Raman product line as well as the company’s overall growth strategy. Financial details of the transaction were not disclosed.
B&W Tek will continue to operate under its own brand with its own sales and service organization for the time being to avoid any business disruption. After this transition period, B&W Tek will be gradually integrated into the Metrohm organization.
Source:
Articles in this issue
about 8 years ago
Glycan Analysis: Challenges and Benefits of Outsourcingabout 8 years ago
Assessing the E&L Risk in Biologic Drugsabout 8 years ago
Solutions and Solvents Improve Analytical Instrument Performanceabout 8 years ago
New Mass Spec Software Simplifies Data Analysisabout 8 years ago
Sotera Health’s Nelson Labs Acquires Gibraltar Laboratoriesabout 8 years ago
Enhanced Analysis with New Triple Quadrupole Mass Spectrometerabout 8 years ago
New EBSD Detector Features Advanced Sensors and OpticsAdvertisement
Related to this article
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
How to test pen injector assembly interfaces from URS to FAT and SAT: verify part tracking, reject confirmation, restarts, and data transfer evidence.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Ask the Expert: Choosing Ingredient Suppliers
3
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5